在接受CFTR调节器治疗的囊性纤维化患者中,骨折风险降低
Akin Adio1, Miguel Fiandeiro2, Jehad Feras Alsamhori3
1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Journal of orthopaedics
|January 8, 2026
概括
囊性纤维化转膜导电调节器 (CFTR) 调节器治疗显著降低了囊性纤维化患者的骨折风险. 这种治疗提供了骨保护,扩展了除肺部和营养健康之外的好处.
科学领域:
- 医学研究 医学研究
- 肺部病理学 肺部病理学
- 整形外科 整形外科 整形外科
背景情况:
- 囊性纤维化相关的骨病导致CF患者骨折和发病率.
- 囊性纤维化转膜导电调节器 (CFTR) 调节器改善肺部和营养结果.
- CFTR调节器对骨健康的影响尚未完全理解.
研究的目的:
- 评估CFTR调节器治疗对囊性纤维化患者骨折风险的影响.
- 为了比较CFTR调节器暴露和不暴露的CF患者之间的骨折风险.
- 根据特定的CFTR调节器类型 (ETI与非ETI) 分析骨折结果.
主要方法:
- 使用TriNetX研究网络 (168个医疗保健组织) 进行的回顾性队列研究.
- 与5639名CF患者进行CFTR调节器 (2012-2023) 和匹配的对照进行了比较.
- 使用倾向性得分匹配和计算的2年骨折风险 (95%CI的相对风险).
主要成果:
- CFTR调制剂治疗显著降低了整体骨折风险 (RR 0.48,p < .0001).
- 在多个骨折部位 (手,手腕,大腿骨,脊椎等) 观察到保护作用. ) 的情况.
- 与没有治疗相比,ETI和非ETI调节剂都降低了骨折风险;ETI和非ETI之间没有显著差异.
结论:
- 在囊性纤维化患者中,CFTR调节器治疗与较低的2年骨折风险有关.
- 这些发现证明了CFTR调节器的骨保护益处.
- 调节器疗法扩展了其对CF骨健康的积极影响.
更多相关视频
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
11.1K
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
427
相关概念视频
Cystic Fibrosis: Management
465
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
465
Cystic Fibrosis: Pathogenesis
703
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
703
Drugs for Treatment of Constipation-Predominant IBS
698
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
698
Fractures: Bone Repair
5.0K
Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
5.0K
